Duke logo

ATOMIC ARI-AT-002 (Advanced Non-Small Cell Lung Cancer) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if the study drug brigatinib (AP26113) is safe and will work in adults with advanced lung cancer (called non-small cell lung cancer or NSCLC) with ALK rearrangement.

What is the Condition Being Studied?

Advanced non-small cell lung cancer (NSCLC)

Who Can Participate in the Study?

Adults who have confirmed non-small cell lung cancer with gene mutation

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Be given the study drug, brigatinib
-- You will take brigatinib once a day by mouth
- Have blood samples and possibly a small piece of tissue removed from your lung to see what type of lung cancer cells you have
- Have other tests, exams, and procedures for study purposes and your standard of care
- Be in the study for up to 24 months after the start of study drug or until your condition worsens or you have unbearable side effects

Study Details

Full Title
Phase II trial of brigatinib after treatment with second-generation ALK inhibitors in refractory ALK rearranged NSCLC
Principal Investigator
Medical Oncologist
Protocol Number
IRB:PRO00074492
NCT:NCT02706626
Phase
Phase II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
studyrecruitment@duke.edu
or
919-681-5698